From off-period dystonia to peak-dose chorea. The clinical spectrum of varying subthalamic nucleus activity.

The effect of chronic bilateral high-frequency stimulation of the subthalamic nucleus (STN) on levodopa-induced dyskinaesias was investigated in eight patients with fluctuating Parkinson's disease complicated by functionally disabling off-period dystonia. All of the patients also had severe diphasic and peak-dose chorea, so that it was possible to study the effect of high-frequency stimulation on the different types of levodopa-induced dyskinaesias. Off-period fixed dystonia was reduced by 90% and off-period pain by 66%. After acute levodopa challenge, high-frequency stimulation of the STN reduced diphasic mobile dystonia by 50% and peak-dose choreic dyskinaesias by 30%. The effect of bilateral high-frequency stimulation of the STN on the Unified Parkinson's Disease Rating Scale motor score had the same magnitude as the preoperative effect of levodopa. This allowed the levodopa dose to be reduced by 47%. The combination of reduced medication and continuous high-frequency stimulation of the STN reduced the duration of on-period diphasic and peak-dose dyskinaesias by 52% and the intensity by 68%. Acute high-frequency stimulation of the STN mimics an acute levodopa challenge, concerning both parkinsonism and dyskinaesias, and suppresses off-period dystonia. Increasing the voltage can induce repetitive dystonic dyskinaesias, mimicking diphasic levodopa-induced dyskinaesias. A further increase in voltage leads to a shift from a diphasic-pattern dystonia to a peak-dose pattern choreodystonia. Chronic high-frequency stimulation of the STN also mimics the benefit of levodopa on parkinsonism and improves all kinds of levodopa-induced dyskinaesias to varying degrees. Off-period dystonia, associated with neuronal hyperactivity in the STN is directly affected by stimulation and disappears immediately. The effect of chronic high-frequency stimulation of the STN on diphasic and peak-dose dyskinaesias is more complex and is related directly to the functional inhibition of the STN and indirectly to the replacement of the pulsatile dopaminergic stimulation by continuous functional inhibition of the STN. Chronic high-frequency stimulation of the STN allows a very gradual increase in stimulation parameters with increasing beneficial effect on parkinsonism while reducing the threshold for the elicitation of stimulation-induced dyskinaesias. In parallel with improvement of parkinsonism, the levodopa dose can be gradually decreased. As diphasic dystonic dyskinaesias are improved to a greater degree than peak-dose dyskinaesias, both direct and indirect mechanisms may be involved. Peak-dose choreatic dyskinaesias, associated with little evidence of parkinsonism and thus with low neuronal activity in the STN, are improved, mostly indirectly. Fixed off-period dystonia, mobile diphasic dystonia and peak-dose choreodystonia seem to represent a continuous clinical spectrum reflecting a continuous spectrum of underlying activity patterns of STN neurons.

[1]  R. Duvoisin,et al.  Treatment of parkinsonism with levodopa. , 1969, Archives of neurology.

[2]  Anthony E. Lang,et al.  Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP patients requiring levodopa , 1996 .

[3]  J. Penney,et al.  The functional anatomy of basal ganglia disorders , 1989, Trends in Neurosciences.

[4]  Y. Agid,et al.  Does levodopa aggravate Parkinson's disease? , 1988, Neurology.

[5]  M. Mark,et al.  Ten years' experience with enteral levodopa infusions for motor fluctuations in Parkinson's disease , 1998, Movement disorders : official journal of the Movement Disorder Society.

[6]  A Benazzouz,et al.  Stimulation of subthalamic nucleus alleviates tremor in Parkinson's disease , 1997, The Lancet.

[7]  D. Brooks,et al.  Core assessment program for intracerebral transplantations (CAPIT) , 1992, Movement disorders : official journal of the Movement Disorder Society.

[8]  W. Weiner,et al.  Dystonic foot response of Parkinsonism. , 1980, Archives of neurology.

[9]  Y. Agid,et al.  Levodopa‐induced dyskinesias in Parkinson's disease phenomenology and pathophysiology , 1994, Movement disorders : official journal of the Movement Disorder Society.

[10]  W. Gibb,et al.  A comparison of clinical and pathological features of young‐ and old‐onset Parkinson's disease , 1988, Neurology.

[11]  A. Benabid,et al.  Effect on parkinsonian signs and symptoms of bilateral subthalamic nucleus stimulation , 1995, The Lancet.

[12]  M. Hallett,et al.  Pallidotomy for hemiballismus: Efficacy and characteristics of neuronal activity , 1997, Annals of neurology.

[13]  W. Poewe,et al.  Dystonia in parkinson's disease: Clinical and pharmacological features , 1988, Annals of neurology.

[14]  W. Poewe,et al.  Foot dystonia in Parkinson's disease: clinical phenomenology and neuropharmacology. , 1987, Advances in neurology.

[15]  A. Barbeau Long-term side-effects of levodopa. , 1971, Lancet.

[16]  H. Bergman,et al.  The primate subthalamic nucleus. II. Neuronal activity in the MPTP model of parkinsonism. , 1994, Journal of neurophysiology.

[17]  H. Narabayashi,et al.  Levodopa-induced dyskinesia and thalamotomy. , 1984, Journal of neurology, neurosurgery, and psychiatry.

[18]  P. Bédard,et al.  Cabergoline, a long-acting dopamine D2-like receptor agonist, produces a sustained antiparkinsonian effect with transient dyskinesias in parkinsonian drug-naive primates , 1996, Brain Research.

[19]  J. Obeso,et al.  The role of pulsatile versus continuous dopamine receptor stimulation for functional recovery in Parkinson's disease. , 1994, The European journal of neuroscience.

[20]  J. Dostrovsky,et al.  Effect of GPi pallidotomy on motor function in Parkinson's disease , 1995, The Lancet.

[21]  M. Riklan,et al.  Chemopallidectomy and chemothalamectomy for parkinsonism. , 1958, Geriatrics.

[22]  A. Benabid,et al.  Long-term suppression of tremor by chronic stimulation of the ventral intermediate thalamic nucleus , 1991, The Lancet.

[23]  S. Fahn Fluctuations of disability in Parkinson's disease: pathophysiology , 1981 .

[24]  A. Benabid,et al.  Chronic stimulation of subthalamic nucleus improves levodopa-induced dyskinesias in Parkinson's disease , 1997, The Lancet.

[25]  A. Lang,et al.  Utility of an objective dyskinesia rating scale for Parkinson's disease: Inter‐ and intrarater reliability assessment , 1994, Movement disorders : official journal of the Movement Disorder Society.

[26]  F. Calon,et al.  Continuous or pulsatile chronic D2 dopamine receptor agonist (U91356A) treatment of drug-naive 4-phenyl-1,2,3,6-tetrahydropyridine monkeys differentially regulates brain D1 and D2 receptor expression: in situ hybridization histochemical analysis , 1997, Neuroscience.

[27]  J. P. Martin HEMICHOREA RESULTING FROM A LOCAL LESION OF THE BRAIN. (THE SYNDROME OF THE BODY OF LUYS , 1927 .

[28]  T. Engber,et al.  Contribution of dopaminergic and glutamatergic mechanisms to the pathogenesis of motor response complications in Parkinson's disease. , 1996, Advances in neurology.

[29]  M. Horstink,et al.  Severity of Parkinson's disease is a risk factor for peak-dose dyskinesia. , 1990, Journal of neurology, neurosurgery, and psychiatry.

[30]  B. Gomez-Mancilla,et al.  DOPA-induced "peak dose" dyskinesia: clues implicating D2 receptor-mediated mechanisms using dopaminergic agonists in MPTP monkeys. , 1995, Journal of neural transmission. Supplementum.

[31]  I. S. Cooper,et al.  The effect of subcortical lesions on production and alleviation of hemiballic or hemichoreic movements. , 1966, Journal of the neurological sciences.

[32]  F. Mundinger [Subthalamotomy for the treatment of extrapyramidal movement disorders]. , 1965, Deutsche medizinische Wochenschrift.

[33]  F. Mcdowell,et al.  “Early” initiation of levodopa treatment does not promote the development of motor response fluctuations, dyskinesias, or dementia in Parkinson's disease , 1991, Neurology.

[34]  Niall Quinn,et al.  Young onset Parkinson's disease , 1987, Movement disorders : official journal of the Movement Disorder Society.

[35]  George C. Cotzias,et al.  Modification of Parkinsonism--chronic treatment with L-dopa. , 1969, The New England journal of medicine.

[36]  Jean Siegfried,et al.  Bilateral chronic electrostimulation of ventroposterolateral pallidum: a new therapeutic approach for alleviating all parkinsonian symptoms. , 1994 .

[37]  A. Barbeau L-dopa therapy in Parkinson's disease: a critical review of nine years' experience. , 1969, Canadian Medical Association journal.

[38]  A. Benabid,et al.  Electrical stimulation of the subthalamic nucleus in advanced Parkinson's disease. , 1998, The New England journal of medicine.

[39]  L. Cote,et al.  Painful dystonic spasms in Parkinson's disease. , 1984, Advances in neurology.

[40]  Y. Agid,et al.  Pathophysiology of L-dopa-induced abnormal involuntary movements. , 1985, Psychopharmacology. Supplementum.

[41]  J. Obeso,et al.  Levodopa‐induced dyskinesias in Parkinson's disease: Clinical and pharmacological classification , 1992, Movement disorders : official journal of the Movement Disorder Society.

[42]  A. Barbeau Six years of high-level levodopa therapy in severely akinetic parkinsonian patients. , 1976, Archives of neurology.

[43]  S Blond,et al.  Chronic thalamic stimulation improves tremor and levodopa induced dyskinesias in Parkinson's disease. , 1993, Journal of Neurology Neurosurgery & Psychiatry.

[44]  L. Schiffer,et al.  Aromatic amino acids and modification of parkinsonism. , 1967, The New England journal of medicine.

[45]  B Bioulac,et al.  Reversal of Rigidity and Improvement in Motor Performance by Subthalamic High‐frequency Stimulation in MPTP‐treated Monkeys , 1993, The European journal of neuroscience.

[46]  A L Benabid,et al.  Abnormal involuntary movements induced by subthalamic nucleus stimulation in parkinsonian patients , 1996, Movement disorders : official journal of the Movement Disorder Society.

[47]  M. Sambrook,et al.  Thalamotomy for the alleviation of levodopa-induced dyskinesia: Experimental studies in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated parkinsonian monkey , 1993, Neuroscience.

[48]  P. Stewart PARALYSIS AGITANS;: WITH AN ACCOUNT OF A NEW SYMPTOM , 1898 .

[49]  I. S. Cooper SURGICAL ALLEVIATION OF PARKINSONISM: EFFECTS OF OCCLUSION OF THE ANTERIOR CHOROIDAL ARTERY * , 1954, Journal of the American Geriatrics Society.

[50]  A. Lees,et al.  "OFF PERIOD" DYSTONIA AND "ON PERIOD" CHOREOATHETOSIS IN LEVODOPA-TREATED PATIENTS WITH PARKINSON'S DISEASE , 1977, The Lancet.

[51]  N H Holford,et al.  The response to levodopa in parkinson's disease: Imposing pharmacological law and order , 1996, Annals of neurology.

[52]  M. Yahr,et al.  Parkinson's disease and long-term levodopa therapy. , 1987, Advances in neurology.

[53]  S. Fahn Unified Parkinson's Disease Rating Scale , 1987 .

[54]  A J Lees,et al.  Continuous subcutaneous waking day apomorphine in the long term treatment of levodopa induced interdose dyskinesias in Parkinson’s disease , 1998, Journal of neurology, neurosurgery, and psychiatry.

[55]  S. Gill,et al.  Bilateral dorsolateral subthalamotomy for advanced Parkinson's disease , 1997, The Lancet.

[56]  C. Gervason,et al.  Levodopa‐induced diphasic dyskinesias improved by subcutaneous apomorphine , 1992, Movement disorders : official journal of the Movement Disorder Society.

[57]  J. Dostrovsky,et al.  Effects of apomorphine on globus pallidus neurons in parkinsonian patients , 1997, Annals of neurology.

[58]  E. Melamed Early-morning dystonia. A late side effect of long-term levodopa therapy in Parkinson's disease. , 1979, Archives of neurology.

[59]  J. Bennett,et al.  Suppression of dyskinesias in advanced Parkinson's disease , 1993, Neurology.

[60]  L. Metman,et al.  Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease , 1998, Neurology.

[61]  A. Benabid,et al.  Chronic electrical stimulation of the ventralis intermedius nucleus of the thalamus as a treatment of movement disorders. , 1996, Journal of neurosurgery.

[62]  T. Chase,et al.  Pathogenesis of dyskinesias in parkinson's disease , 1989, Annals of neurology.

[63]  J. Schneider Levodopa-induced dyskinesias in parkinsonian monkeys: Relationship to extent of nigrostriatal damage , 1989, Pharmacology Biochemistry and Behavior.

[64]  A. Lang,et al.  Severe evening dyskinesias in advanced Parkinson's disease: Clinical description, relation to plasma levodopa, and treatment , 2004, Movement disorders : official journal of the Movement Disorder Society.

[65]  C. Marsden,et al.  PAINFUL PARKINSON'S DISEASE , 1986, The Lancet.

[66]  M. Muenter,et al.  Patterns of dystonia ("I-D-I" and "D-I-D-") in response to l-dopa therapy for Parkinson's disease. , 1977, Mayo Clinic proceedings.

[67]  A L Benabid,et al.  Subthalamic nucleus or internal pallidal stimulation in young onset Parkinson's disease. , 1998, Brain : a journal of neurology.

[68]  The pharmacology of foot dystonia in parkinsonism. , 1987, Clinical neuropharmacology.

[69]  A. Benabid,et al.  Opposite motor effects of pallidal stimulation in Parkinson's disease , 1998, Annals of neurology.

[70]  A. Lees,et al.  Beginning-of-dose motor deterioration following the acute administration of levodopa and apomorphine in Parkinson's disease. , 1992, Journal of neurology, neurosurgery, and psychiatry.

[71]  C. Marsden,et al.  Recent Developments in Parkinson's Disease , 1986 .

[72]  M. Hariz,et al.  Leksell's posteroventral pallidotomy in the treatment of Parkinson's disease. , 1992, Journal of neurosurgery.

[73]  J. Dostrovsky,et al.  Globus pallidus internus pallidotomy for generalized dystonia , 1997, Movement disorders : official journal of the Movement Disorder Society.

[74]  L. Grégoire,et al.  Risk Factors for Peak Dose Dyskinesia in 100 Levodopa-treated Parkinsonian Patients , 1996, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[75]  P. Sonsalla,et al.  Complex dystonia of Parkinson's disease: clinical features and relation to plasma levodopa profile. , 1990, Clinical neuropharmacology.

[76]  S. Iversen,et al.  Nigrostriatal damage is required for induction of dyskinesias by L-DOPA in squirrel monkeys. , 1990, Clinical neuropharmacology.

[77]  C D Marsden,et al.  Dopa‐responsive dystonia , 1991, Neurology.

[78]  O. Devinsky,et al.  Stereotactic ventral pallidotomy for Parkinson's disease , 1995, Neurology.

[79]  R. Turner,et al.  Treatment of advanced Parkinson's disease by posterior GPi pallidotomy: 1‐year results of a pilot study , 1996, Annals of neurology.

[80]  M. Mark,et al.  The rationale for continuous dopaminergic stimulation in patients with Parkinson's disease , 1992, Neurology.

[81]  D. Calne,et al.  Pallidotomy for tardive dyskinesia , 1997, The Lancet.

[82]  H. Bergman,et al.  Reversal of experimental parkinsonism by lesions of the subthalamic nucleus. , 1990, Science.

[83]  Mones Rj,et al.  Analysis of l-dopa induced dyskinesias in 51 patients with Parkinsonism , 1971 .

[84]  J. Jankovic,et al.  Pallidotomy for generalized dystonia , 1998, Movement disorders : official journal of the Movement Disorder Society.

[85]  I. Heuser,et al.  Modification of central dopaminergic mechanisms by continuous levodopa therapy for advanced Parkinson's disease , 1990, Annals of neurology.